Image

COVID-19 treatment by Seraph Apheresis



Early clinical trial results on a revolutionary medical device is showing significant potential for use against the COVID-19 infection.

The Gorta Group is set to distribute a blood purification device that has shown promise in treating patients affected by Coronavirus.

The Group recently reached agreement with US manufacturers ExThera Medical for the distribution for humanitarian purposes in Africa and Asia of the Seraph 100, a blood filter therapy that can remove pathogens from the blood.

The Seraph 100 received approval from the US Food and Drug Administration (FDA) in April, following on from its earlier European approval. Early results in COVID-19 patients show lower blood pathogen levels and improvements in mean arterial pressure and oxygen saturation.

The new agreement will enable The Gorta Group to distribute the Seraph 100 in 65 countries in Africa and Asia, and provide the device at low cost to NGOs, government organisations and their agents for medical purposes.

The aim of the public private partnership between the Gorta Group and ExThera Medical is to ensure that world class medical devices are made accessible in a timely manner and at an affordable cost in lower and middle income countries, said Gorta Group CEO Ray Jordan.

“This partnership will enable us to save lives by strengthening public health systems ability to respond to COVID-19. ExThera’s commitment to simultaneously deploy the Seraph 100 globally into both higher income country healthcare systems at market prices and humanitarian led programs at a significant discount should be a beacon for others to follow.”

The Seraph 100 is the first device ever approved for the reduction of pathogens in blood.

Image

At this time there is no other blood purification therapy known to bind and remove bloodborne SARS-CoV-2 virus/RNA while also improving vital signs and laboratory parameters associated with inflammation and tissue damage.

In the treatment of bacterial infections, Seraph 100 has quickly reduced drug-resistant bloodstream pathogens and consistently improved patients’ oxygen saturation. The removal of SARS-CoV-2 virus from the patient’s blood, together with the ability to treat secondary bacterial infections makes Seraph 100 therapy unique in the treatment of COVID-19.

In contrast to other blood purification technologies which only remove molecules, Seraph 100 also quickly lowers the concentration of viruses, bacteria and fungi in whole blood. In pre-clinical testing and in clinical use, Seraph 100 has been shown to significantly reduce the bloodstream concentration of both drug-susceptible and drug-resistant pathogens, providing a long-awaited therapy that addresses the severe problem of drug-resistance, and new and future microbial threats like the COVID-19 virus.

About ExThera Medical
ExThera Medical Corporation is a privately held medical device company developing innovative blood filters capable of removing a broad range of harmful substances from blood. It is led by an accomplished management team with decades-long experience in the development and manufacture of blood-contacting implants, devices, and enabling biomaterials technology. For more information, see www.extheramedical.com